Remidio, received CDSCO approval for its Medios DR AI, which is used with its portable retinal cameras. This approval comes after the same solution received CE marking under EU-MDR guidelines and HSA ...

Tinlarebant is an oral therapy designed to reduce the accumulation of vitamin A based toxins that cause retinal disease.

According to the company, the axitinib injectable suspension achieved all primary and secondary outcomes and maintained stable visual acuity and anatomical control over 9 months. There were no ocular ...

Everads suprachoroidal delivery technology is designed to enable safe and effective in-office delivery of therapies to the choroidal and retinal tissues via the suprachoroidal space. Everads Therapy ...

The retina space continues to see new advancements and clinical trial results, many of which are shared at industry conferences throughout the year. The medical community, and especially the ...

Alfonso Savastano, MD, PhD spoke about the SING-IMT implant during his interview with Ophthalmology Times Europe, which took place at the EURETINA 2024 meeting held in Barcelona, Spain, on September ...

Chinese researchers reported finding β-amyloid (Aβ) deposits along the ocular glymphatic system in patients with Alzheimer's disease (AD) and in a 5×FAD transgenic mouse model, 1 according to Dr.

Taiji Sakamoto, MD, PhD, spoke about being a board member of EURETINA and his motivations to be a part of the cooperative work that is a hallmark of EURETINA. The interview took place at the EURETINA ...

Enrico Borrelli, MD, FEBO, speaks about opportunities in the retina space At this year's EURETINA Congress, we caught up with Enrico Borrelli, MD, FEBO, during a break from his busy schedule. He is ...

Srinivas R. Sadda, MD, spoke about the EURETINA meeting, his presentation on ultra widefield imaging, and the value of the international community of retina clinicians connecting in person at meetings ...

Brepocitinib is a potential first-in-class dual selective inhibitor of TYK2 and JAK1. Priovant Therapeutics has enrolled the first patients in the CLARITY Phase 3 study evaluating brepocitinib in ...